Article Text
Abstract
Cardiac amyloidosis is a rare condition with an estimated incidence of 18–55 per 100 000 person-years. It is associated with either immunoglobulin light chain (AL) or transthyretin amyloid (ATTR), both of which result in a restrictive cardiomyopathy complicated initially by diastolic dysfunction and subsequently followed by biventricular systolic heart failure. Untreated cardiac amyloidosis carries an extremely poor prognosis with an estimated median survival time of less than 1 year in AL and 4 years in ATTR amyloidosis. This is the sixth described report of coronary artery bypass grafting in patients with underlying cardiac amyloidosis.
- Arrhythmias
- Cardiovascular system
- Haematology (drugs and medicines)
- Chemotherapy
- Pathology
Statistics from Altmetric.com
Footnotes
Contributors IA, JL and CH were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms, critical revision for important intellectual content, and gave final approval of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.